Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LA-SN38
- Development stage
- Preclinical
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LA-SN38 is a *lipophilic prodrug of SN-38*, created by covalently linking the unsaturated fatty acid linoleic acid (LA) to SN-38, the active metabolite of irinotecan. This modification enhances the hydrophobicity and enables highly efficient encapsulation into PEGylated liposomes, resulting in improved tumor cell uptake, prolonged systemic circulation, and decreased clearance by macrophages. LA-SN38 displays higher cytotoxicity and antitumor efficacy in colorectal cancer cell lines and xenograft models compared to conventional SN-38 or CPT-11 (irinotecan), with reduced systemic toxicity. Mechanistically, LA-SN38 acts as a precursor, releasing SN-38, which inhibits *DNA topoisomerase I* and thereby interferes with DNA replication in tumor cells, promoting S-phase cell death[2].
- Other names
- LA-SN38LA-SN-38LA-SN 38
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on LA-SN38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LA-SN38.